Efficacy and tolerability of intensity-modulated radiotherapy (IMRT) with cisplatin (CDDP) versus cetuximab (CTX) and nimotuzumab (NTZ) for Stage II-IVb Nasopharyngeal Carcinoma (NPC).

Trial Profile

Efficacy and tolerability of intensity-modulated radiotherapy (IMRT) with cisplatin (CDDP) versus cetuximab (CTX) and nimotuzumab (NTZ) for Stage II-IVb Nasopharyngeal Carcinoma (NPC).

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Nimotuzumab (Primary)
  • Indications Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Oct 2017 New trial record
    • 15 Sep 2017 Results of multivariate analysis and subgroup analysis assessing Efficacy and safety were compared between the CTX/NTZ and CDDP groups, were published in the International Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top